Hikers sitting on a mountaintop overlooking a vast plain

Empowering Healthier Lives

We believe that fast, accurate point of care testing empowers people to enjoy healthier, more informed lives.

Consumers are embracing the power of at-home diagnostics and telehealth.

The Opportunity

This is a pivotal moment in healthcare. Increased consumer acceptance of telemedicine and the need for faster information has generated even greater demand for rapid point of care diagnostics.

Atomo has developed the most consumer friendly platform available for blood-based rapid at-home testing. Our integrated testing technology helps revolutionise access to healthcare solutions and deliver improved healthcare outcomes. We are a world leader in rapid testing solution that puts the user in the centre of the testing experience.

Our technology, which is easy to use, safe, reliable, and intuitive, is uniquely positioned to support the growing demand for affordable point of care monitoring of health and at-home testing.

Woman holding a small white plastic component

Our Story

After ten years as a senior leader in the medical device sector, Atomo’s Founder and CEO John Kelly identified multiple ways in which diagnostics were ripe for transformation. John observed that usability, convenience, and simplicity of use could make a real difference in diagnostics. When people can’t use a product the way it is intended, the performance is undermined.

While John was exploring areas of the market where usability was poorly delivered, his youngest daughter was born and required intensive medical care for the first two years of her life. He watched as doctors struggled to collect blood from her arm. When John found out that the blood test they were doing only required a tiny drop of blood, he had a light bulb moment. John decided to develop a better, less invasive way to collect a blood sample.

Vision & Mission

Empowering people to enjoy healthier, more informed lives through fast, accurate point of care testing. We are re-imagining diagnostics by putting the user experience at the centre of everything we do. Atomo's mission is to ensure equitable and affordable access to accurate diagnoses and promote a seamless pathway to treatment.

Values

Black and white logo featuring a star at its center

Impact

Commercialising products that matter to our users

A light bulb with gears inside, symbolising innovation and creativity

Innovation

Fostering creative thinking and solutions

Image of a scale symbolising justice and integrity

Integrity

Ensuring honesty and fairness in all that we do

Puzzle piece on white background, symbolising problem solving and teamwork

Collaboration

Working as one
global team

A gleaming silver trophy on a plain white background, symbolising achievement and success

Excellence

Being recognised as experts in the field

Executive Team

Classic black and white photograph featuring a sharply dressed man in a suit.

John Kelly

Founder, Managing Director & CEO

For more than 20 years John Kelly has championed the cause of reimagining medical devices to enhance their usability and performance. Before founding Atomo Diagnostics in 2010, John was Chief Operating Officer at ASX listed (now NASDAQ listed) Unilife Corporation, where he led the ‘Unifill’ development team to develop the world’s first glass prefilled drug delivery device with integrated auto retract safety feature. This technology was successfully licensed to Sanofi Aventis. Previously, John led the New Product Implementation Group at ResMed, where he managed the design and commercialisation of the ground-breaking Mirage Swift mask. In addition to his commercial experience, John has an Honours Degree in Mechanical Engineering from the University of Liverpool, a Master’s Degree in Systems Engineering from Queen’s University Belfast, and an Executive MBA from the University of Sydney, where he was awarded the Business School’s inaugural ‘Excellence in Leadership’ scholarship.

Professional photo shoot of woman in black and white

Chandra Sukumar

Chief Operating Officer

Chandra joined Atomo in 2017 as Director of Programs bringing with her more than 25 years of experience within the medical device industry. She has extensive experience in the development of medical devices from conception to commercialisation. Prior to joining Atomo, she served in a variety of leadership roles within ResMed, including supply chain management, global manufacturing, and APAC marketing. Chandra holds a Bachelors Honours degree in Physics and an executive MBA from AGSM.

Board of Directors

A monochrome image featuring a well-dressed man in a suit, exuding elegance and sophistication.

John Keith

Non-Executive Chair

John is the Managing Director of BNP Paribas. Prior to that, he led management and coverage roles for Nomura Securities in Sydney and Hong Kong. John also serves as a Director of ASIA Limited, Calliva Limited, Room to Read Australia Foundation and Ascham Foundation.

Classic black and white photograph featuring a sharply dressed man in a suit.

Dr. Paul Kasian

Non-Executive Director

Chair of IODM Limited. Non-Executive Director of Eco Systems Ltd (ASX:ESL). Previously Chair and CEO of Genetic Technologies Limited. PhD in Microbiology and MBA, both from the University of Melbourne, and GAICD. Former Chief Investment Officer and Head of Global Financials at HSBC Asset Management; Founding Director of Accordius; Founding Director of Wallara Asset Management.

A monochrome image capturing a woman's joyful expression with a smile on her face.

Deborah J. Neff

Non-Executive Director

A veteran of the life sciences industry building market-leading global businesses. As principal of DJN Consulting, LLC. based in the San Francisco Bay Area, Deborah currently works with several privately held healthcare startup companies providing strategic business advice to and mentoring the executive management team. Previously CEO of Evanostics, LLC. and Pathwork Diagnostics Inc., and COO at Complete Genomics Inc., following a 15-year career with Becton Dickinson, Inc. where she last served as President of BDBiosciences, a major global business unit of the company. Former non-executive director of Bio-Rad, Inc., ForteBio, Inc. (acquired by Pall Corp) and AMO Inc., (acquired by Abbott). Deborah served as a board member and executive advisor for Galt Inc., and Vortex Biosciences Inc. She is an Executive Trustee of the UCDavis Foundation Board and also chairs the College of Biological Sciences Dean’s Leadership Council at the University.

A woman with long hair wearing a black shirt.

Dr. Cheri Walker

Non-Executive Director

Dr. Walker is an executive with more than twenty-five years of experience working with life science and diagnostic companies. Employing years in the financial markets as a stock analyst, commercial execution to meet aggressive growth targets, and more than 45 successfully closed mergers, acquisitions and divestitures, she has worked as part of and with management teams, private equity and venture firms to develop the best strategies to build their life science business and to execute on acquisition strategies or sale of the company. Dr. Walker is currently the President, Chief Executive Officer, and Director of Rhinostics, an early-stage spin-out company based on technology initially developed at Harvard University. She has previously held senior executive positions at Abcam; Charles River Labs; Qiagen, and Life Technologies, now part of ThermoFisher. Dr. Walker holds a BA in Biology from Swarthmore College and a Ph.D. in Human and Molecular Genetics from Baylor College.

Work With Us

Atomo is a fast-growing dynamic company with tremendous opportunities for people interested in revolutionising healthcare through rapid point-of-care diagnostics.

We’re looking for energetic, creative, entrepreneurial people who have a keen interest in using technology to make the world a better place.

If you would like to join our team, please email careers@atomodiagnostics.com.

Two men in white lab coats examining a clipboard
A monochrome picture of a man and woman standing together, captured in black and white.

Re-imagining diagnostics